AbbVie: Lung Neoplasms trials
The registry lists 11 Lung Neoplasms studies with AbbVie as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 7Phase 2 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
- A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid TumorsCompletedNCT02033551Phase 1
- A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid TumorsCompletedNCT02009631Phase 1
- Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)TerminatedNCT00373204Phase 2
- Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung CancerTerminatedNCT00365183Phase 2
- A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung CancerCompletedNCT00297089Phase 1/2
- Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung CancerCompletedNCT00129844Phase 2
- Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain MetastasesTerminatedNCT00121420Phase 2
- Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1
- A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00102505Phase 1
- Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1